Objectives: Unsedated office-based laryngeal laser surgery (UOLS) is now an effective alternative to traditional operating room-based suspension microdirect laryngoscopy under general anesthesia. This procedure includes pulsed dye laser (PDL) treatment of recurrent respiratory papillomas, granulomas, leukoplakia, and polypoid degeneration. The objective of this study was to determine the magnitude of the cost savings derived by moving these types of procedures from the operating room to the office setting.
INTRODUCTION
Unsedated office-based laryngeal laser surgery (UOLS) has recently emerged as an effective alternative to traditional operating room (OR)-based suspension microdirect laryngoscopy performed with the patient under general anesthesia. This procedure includes pulsed dye laser (PDL) treatment of recurrent respiratory papillomas, granulomas, leukoplakia, and polypoid degeneration. These in-office surgeries offer substantial cost savings to patients, insurance companies, and the health care system in general. However, at present, this cost savings has not been recognized by third-party payers, and reimbursement has been a challenge. It is important for third-party payers to recognize the substantial reduction in medical costs achieved by avoidance of general anesthesia, OR use, and hospitalization.
The objective of this study was to identify and compare the costs of laser surgeries for recurrent respiratory papillomatosis (RRP) in the OR and unsedated in the office setting. METHODS This study was approved by the Wake Forest University Health Sciences Institutional Review Board.
Using surgical CPT codes, we identified 6 consecutive patients who underwent carbon dioxide (CO2) laser surgery for RRP in the OR from January 2003 to January 2006. Using the office PDL log, we identified 7 consecutive patients who underwent UOLS for RRP during the same time period. The itemized billing records, including physician charges, for each of these groups were retrospectively reviewed and compared.
The surgical techniques used for treating RRP with the PDL have been detailed in other publications. 1, 2 
RESULTS
The average age for the OR group was 53.5 years (range, 34 to 78 years), and that for the UOLS group was 57.5 years (range, 34 to 98 years). Table 1 shows the breakdown of charges for the OR group. Incidental charges that varied from patient to patient (such as pathology charges or cidofovir usage) were excluded from the analysis. Preoperative assessment clinic charges include preoperative laboratory studies and electrocardiograms for some of the subjects. The "drugs" category includes both anesthetic drugs and surgical drugs (such as lidocaine). The average total charges were $7,808 for OR RRP surgeries and $2,081 for UOLS, resulting in an average savings of $5,727 for UOLS. To look at the data in a more general way, the minimum, maximum, and average for each charge category were analyzed (rather than looking at these charges for each subject). Examining the data in this manner revealed a similar reduction in charges of $5,801 for UOLS versus OR RRP treatment, with a range of $2,922 to $8,605.
DISCUSSION
Significant cost savings could be realized by moving certain laryngeal procedures from the OR to the office. Other studies have indicated that office procedures are cost-saving compared to OR surgeries. For example, laser-assisted uvulopalatoplasty performed in the office has been shown to generate a cost savings of approximately $8,100 when compared to uvulopalatopharyngoplasty performed in the OR with an overnight hospital stay. 4 By avoiding general anesthesia, UOLS presents less risk to the patient than suspension microdirect laryngoscopy in the OR. The risks of UOLS for RRP include epistaxis, vasovagal episodes, and local anesthetic toxicity. Pneumothorax is a theoretical but unreported complication of UOLS. In the OR, the risks include airway obstruction, pneumothorax, general anesthetic reactions, injury to the teeth and tongue from the laryngoscope, and inadvertent CO2 laser burns and fires.
The PDL has been shown in numerous studies to have good efficacy for RRP treatment. 2, 5, 6 RRP is a chronic disease for which there is no cure; therefore, treatments are aimed at surgical debulking for maintenance of an adequate airway and satisfactory voice. The PDL is a 585-nm wavelength laser transmitted via a flexible fiber that can be used in the office through the working channel of a 5.1-mm transnasal esophagoscope. The PDL works via selective photothermolysis, and it is thought to be epithelialsparing and hence an excellent wavelength choice in the larynx. 2, 7, 8 The indications for use of the PDL also have been expanded to include leukoplakia, 2,9 laryngeal granulomas, 10 and Reinke's edema (unpublished observations).
In chronic processes such as RRP, leukoplakia, and laryngeal granuloma, patient quality of life is an important outcome to consider. These disorders typically require multiple treatments, and the time commitment and inconvenience for the patients cannot be discounted. The cost savings and patient time savings will be repeated each time that surgery is required. We have found that many of our patients prefer to have RRP procedures in the office without sedation. In a recent survey of 89 patients who had undergone UOLS with the PDL in the upper aerodigestive tract, respondents indicated that the procedure was remarkably well tolerated, with only mild discomfort, primarily perceived in the throat rather than the nose. 11 Of these 89 subjects, 61% had undergone previous treatments for the same disorder in the OR. Eighty-three percent of this group reported less discomfort with UOLS, and 87% indicated a preference for UOLS over surgery in the OR. For those subjects who preferred UOLS, the reasons cited included saving time (55%), saving money (32%), improving comfort (62%), and avoiding the risks of general anesthesia (28%). These values total more than 100% because many patients cited multiple reasons for preferring UOLS.
In our practices, new patients who present with RRP are currently taken to the OR for suspension microdirect laryngoscopy to obtain pathologic specimens and to explore the larynx for extent of disease (especially the laryngeal ventricles). During this surgery, the suitability for office-based procedures is ascertained, and patients are frequently offered UOLS for their future treatments.
This report represents a cost identification analysis only. 12 It is not possible to accurately perform a cost-benefit analysis in this case, because the true effectiveness of UOLS in the treatment of RRP is not clear. Certainly, many authors have reported good efficacy of the PDL for RRP, 2,5,6 but a true efficacy comparison of OR CO2 laser surgeries and officebased PDL procedures evaluating symptom-free intervals has not been performed. To understand these data in the context of a cost identification analysis, one must assume that these two procedures have equal efficacy for RRP. However, anecdotal data at this voice center suggest that some patients may need more frequent UOLS compared to OR surgeries for the same burden of disease. This difference might confound the interpretation of the results presented herein. Finally, because these data represent charges only, they have the most impact on the payer (ie, the insurance company), rather than the patient or the surgeon. Some cost factors could not be quantified for inclusion in this study. For example, patients who undergo general anesthesia will always miss at least 1 or 2 days of work. In contrast, patients can go back to work immediately after their unsedated PDL procedure, if they so choose. Global medical costs, such as staffing, are also difficult to quantify. A patient who undergoes surgery in the OR requires the participation of many health care workers (preoperative assessment clinic staff, preoperative holding room staff, two operating room nurses, anesthesia nurses and faculty, the surgeon, postoperative recovery room staff, and possibly hospital floor nurses and nursing aids). For UOLS, the participation of one surgeon and one nurse are required. A nurse or nursing aid is also responsible for processing the endoscope, which requires 30 minutes, mostly unattended. The vast majority of patients who undergo UOLS do not require any pain medicine, further reducing prescription and over-the-counter drug costs. Therefore, the actual cost savings of UOLS for the health-care system and society may be far greater than this report suggests.
It is important to note that performing the procedure in the office does not save time or money for the surgeon or the clinical practice. The cost savings apply to the patient and/or third-party payers. These data represent charges only; the actual reimbursement is much less, depending on the payer. At our institution, the reimbursement rate for UOLS currently varies from about $260 to about $434 for Medicaid, Medicare, and the major local insurance carriers. For the majority of payers, the patient is not required to pay the remaining bill not covered by the third-party payer. For the clinical practice, the PDL equipment requires an initial investment of approximately $80,000. A typical transnasal esophagoscope costs approximately $18,900, and the endoscope processor costs $23,100. Individual PDL fibers are priced at $147 each, and one fiber is used for each patient. In addition, the dye kit (which has a 20,000pulse capacity) costs $900 and must be replaced approximately every 6 months. For example, if a practice were to perform 50 UOLS procedures per year for 5 years, the cost to the practice would be close to $500 per procedure for equipment alone. Addition-ally, each procedure takes 20 to 30 minutes of the surgeon's undivided attention during clinic office hours. Compensation for these costs to the surgeon must be considered in establishing reimbursement rates if there is to be an incentive for moving these procedures to the office.
CONCLUSIONS
The cost savings from UOLS are tremendous, and yet current levels of reimbursement do not even cover the costs of performing the surgeries. The driving force in the proliferation of these exciting and costsaving new technologies will depend upon reconciliation of cost-payment issues.
